Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.55
- Piotroski Score 3.00
- Grade Buy
- Symbol (IPSC)
- Company Century Therapeutics, Inc.
- Price $1.33
- Changes Percentage (5.56%)
- Change $0.07
- Day Low $1.25
- Day High $1.43
- Year High $5.51
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $22.00
- High Stock Price Target $27.00
- Low Stock Price Target $9.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.22
- Trailing P/E Ratio -1.32
- Forward P/E Ratio -1.32
- P/E Growth -1.32
- Net Income $-136,673,000
Income Statement
Quarterly
Annual
Latest News of IPSC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Lipscomb takes on No. 16 Arkansas following Ognacevic's 30-point game
Lipscomb faces No. 16 Arkansas next, following Jacob Ognacevic's 30-point performance in their recent win....
By AP NEWS | 15 hours ago -
Duquesne hosts Lipscomb to open season
Duquesne will kick off the season at home against Lipscomb. Duquesne had a strong 25-12 record, shooting 43.6% from the field. Lipscomb had a 20-12 record, allowing 76.5 points per game and shooting 4...
By AP NEWS | 2 days ago -
Lipscombe kicks 4 field goals, defense has 4 takeaways, Presbyterian tops Dayton 28-7
Presbyterian defeated Dayton 28-7 with Peter Lipscombe's field goals and Tariq Hollinger's fumble recoveries. Quante Jennings and Worth Warner added touchdowns in the game....
By AP NEWS | 3 days ago
